scholarly journals Near-Infrared Luciferin Analogs for In Vivo Optical Imaging

2021 ◽  
Author(s):  
Ryohei Saito-Moriya ◽  
Rika Obata ◽  
Shojiro A. Maki

The firefly bioluminescence reaction has been exploited for in vivo optical imaging in life sciences. To develop highly sensitive bioluminescence imaging technology, many researchers have synthesized luciferin analogs and luciferase mutants. This chapter first discusses synthetic luciferin analogs and their structure–activity relationships at the luminescence wavelength of the firefly bioluminescence reaction. We then discuss the development of luciferin analogs that produce near-infrared (NIR) light. Since NIR light is highly permeable for biological tissues, NIR luciferin analogs might sensitively detect signals from deep biological tissues such as the brain and lungs. Finally, we introduce two NIR luciferin analogs (TokeOni and seMpai) and a newly developed bioluminescence imaging system (AkaBLI). TokeOni can detect single-cell signals in mouse tissue and luminescence signals from marmoset brain, whereas seMpai can detect breast cancer micro-metastasis. Both reagents are valid for in vivo bioluminescence imaging with high sensitivity.


2015 ◽  
Vol 27 (2) ◽  
pp. 404-413 ◽  
Author(s):  
Kazuhide Sato ◽  
Alexander P. Gorka ◽  
Tadanobu Nagaya ◽  
Megan S. Michie ◽  
Roger R. Nani ◽  
...  


2016 ◽  
Vol 4 (33) ◽  
pp. 5560-5566 ◽  
Author(s):  
Lesan Yan ◽  
Huiquan Wang ◽  
Anqi Zhang ◽  
Calvin Zhao ◽  
Yongping Chen ◽  
...  

The IR780@NPs exhibited excellent characteristics for in vivo imaging with a long circulation time and high retention in tumor and sentinel lymph node.



Nanomaterials ◽  
2012 ◽  
Vol 2 (2) ◽  
pp. 92-112 ◽  
Author(s):  
Chai-Hoon Quek ◽  
Kam W. Leong


2005 ◽  
Vol 102 (8) ◽  
pp. 2922-2927 ◽  
Author(s):  
P. P. Ghoroghchian ◽  
P. R. Frail ◽  
K. Susumu ◽  
D. Blessington ◽  
A. K. Brannan ◽  
...  


2021 ◽  
pp. 105167
Author(s):  
Yong Dae Park ◽  
Mayank Kinger ◽  
Changho Min ◽  
Sang Yeob Lee ◽  
Youngjoo Byun ◽  
...  


2011 ◽  
Vol 14 (3) ◽  
pp. 368 ◽  
Author(s):  
Mi-Sook Lee ◽  
Young Han Kim ◽  
Yeon Joo Kim ◽  
Seung-Hae Kwon ◽  
Jeong-kyu Bang ◽  
...  

Purpose TIMP-2 has been studied as an attractive cancer therapeutic candidate, and a TIMP-2 fusion protein (HSA/TIMP-2) displayed effective anticancer activity, despite a lack of information about its pharmacokinetics (PK) and biodistribution. The purpose of this work was to assess the PK and biodistribution of HSA/TIMP-2 as well as to quantify accumulated HSA/TIMP-2 in tumors. Methods Cy5.5 near-infrared (NIR) fluorescence was conjugated to the HSA/TIMP-2 protein (Cy5.5–HSA/TIMP-2) for monitoring spatio-temporal changes in vivo. For PK and biodistribution analysis, 0.2 μg/g body weight of Cy5.5–HSA/TIMP-2 was injected into MAT-LyLu prostate tumor xenografts, which were then imaged using an IVIS-200 optical imaging system. To quantify the accumulated HSA/TIMP-2 in tumors, we introduced a standard curve with depth-corrected fluorescence measurement. Results In the vascular tube formation assay with human umbilical vein endothelial cells (HUVECs), Cy5.5–HSA/TIMP-2 showed an antiangiogenic effect. In prostate cancer xenografts, Cy5.5–HSA/TIMP-2 exhibited a prolongation of blood half-life to 19.6 h and relatively preferential distribution to the tumor. The amount of tumor-accumulated Cy5.5–HSA/TIMP-2 was calculated to be 4.5 ± 0.5 ng/g body weight at 2 days, representing 2.25 ± 0.25% of the initial dose. Conclusions We evaluated the pharmacokinetic profile and biodistribution of HSA/TIMP-2 with favorable results, providing new information for more effective approaches to cancer therapeutics using HSA/TIMP-2. Additionally, real-time in vivo fluorescence imaging analysis using a depth-corrected standard curve may serve as a platform to quantify biodistributed drug in anticancer therapeutic studies. This article is open to POST-PUBLICATION REVIEW. Registered readers (see “For Readers”) may comment by clicking on ABSTRACT on the issue’s contents page.



2012 ◽  
Vol 22 (12) ◽  
pp. 5503 ◽  
Author(s):  
Pei-Ru Wei ◽  
Shih-Hsun Cheng ◽  
Wei-Neng Liao ◽  
Kun-Che Kao ◽  
Ching-Feng Weng ◽  
...  


2008 ◽  
Vol 2 (1) ◽  
pp. 021920 ◽  
Author(s):  
Peter K. Bachmann


2011 ◽  
Vol 8 (2) ◽  
pp. 583-590 ◽  
Author(s):  
Bryan A. Smith ◽  
Seth T. Gammon ◽  
Shuzhang Xiao ◽  
Wei Wang ◽  
Sarah Chapman ◽  
...  


Sign in / Sign up

Export Citation Format

Share Document